Global Varicose Veins Treatment Market Overview, Analysis and Restraints

The weakening of the vessel walls causes varicose veins, which are abnormally dilated blood vessels. Under the epidermis, these veins seemed to be bloated, twisted clusters of blue or purple veins. Millions of people all around the world suffer from varicose vein disease. Symptoms normally develop around the age of 40, and they mostly affect the legs. If varicose veins cause venous stasis ulcers, phlebitis, thrombosis, venous bleeding, or fungal and bacterial infections, they are dangerous to one's health. According to the American Society of Vascular Surgery, at least 20 to 25 million Americans have varicose veins, with 17 percent of males and 33 percent of women suffering from the condition. The varicose vein treatment report is based on in-depth primary and secondary research conducted regionally to determine the variables driving market growth as well as those impeding it.

The market is driven by factors such as an increase in the incidence of varicose vein disease, an increase in the geriatric population, advanced varicose vein treatment devices, participation in occupations that increase the prevalence of varicose vein treatment, and global technological advancements. Furthermore, as people become more aware of varicose veins, and as new markets develop, there are significant potential in the varicose vein therapy industry.

 

Global Varicose Veins Treatment Market: Restraints

The global varicose veins treatment market is likely to be hampered by a lack of skilled specialists, particularly in emerging economies. Endovenous laser treatment/ablation (ELA) and radiofrequency ablation (ERA) are procedures that require specialised training and equipment for clinicians. According to preliminary findings from the Competition Commission of South Africa's health market probe announced in July 2018, the estimated annual average of doctors per 1,000 patients in the private sector was 1.75 between 2010 and 2014.

 

Varicose Veins Treatment Market

In Asia Pacific, insurance companies do not cover all of a surgery's material costs. As a result, market growth is projected to be hampered to some extent.